Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

A phase II trial of deferoxamine in patients with hormone-refractory metastatic prostate cancer. Cancer Invest 1997;15(4):311-7 PMID: 9246151

Pubmed ID

9246151

Abstract

The management of hormone-refractory metastatic prostate cancer remains a therapeutic dilemma. We report the results of a phase II trial with deferoxamine administrated at a dose of 50 mg/kg (maximum dose 5 g) administered intravenously over 8 hr daily, repeated for 5 days at 4-week intervals for 2 courses. Fourteen patients with advanced hormone-refractory prostate cancer were treated and 28 courses were delivered. Essentially no toxicity was observed. Using combined clinical and prostate-specific antigen (PSA) criteria. 13 of 14 patients had disease progression. However, 9 of 14 patients had stable measurable or evaluable disease and progressed solely based on PSA criteria. Deferoxamine in this dose and schedule has no activity in hormone-refractory prostate cancer. Further investigation of the effect of deferoxamine on PSA production/expression is warranted.

Author List

Dreicer R, Kemp JD, Stegink LD, Cardillo T, Davis CS, Forest PK, See WA

Author

William A. See MD Chair, Professor in the Urologic Surgery department at Medical College of Wisconsin




Scopus

2-s2.0-0030797719   13 Citations

MESH terms used to index this publication - Major topics in bold

Adenocarcinoma
Aged
Antineoplastic Agents
Antineoplastic Agents, Hormonal
Creatinine
Deferoxamine
Drug Resistance, Neoplasm
Humans
Hydroxyproline
Infusions, Intravenous
Lung Neoplasms
Lymphatic Metastasis
Male
Methylhistidines
Middle Aged
Pelvis
Prostatic Neoplasms
jenkins-FCD Prod-336 69ef4a6b262d135130251597d5d39873903802b5